AR123714A1 - Biofactores para el tratamiento y la profilaxis de la demencia - Google Patents

Biofactores para el tratamiento y la profilaxis de la demencia

Info

Publication number
AR123714A1
AR123714A1 ARP210102785A ARP210102785A AR123714A1 AR 123714 A1 AR123714 A1 AR 123714A1 AR P210102785 A ARP210102785 A AR P210102785A AR P210102785 A ARP210102785 A AR P210102785A AR 123714 A1 AR123714 A1 AR 123714A1
Authority
AR
Argentina
Prior art keywords
dementia
prophylaxis
treatment
biofactors
folates
Prior art date
Application number
ARP210102785A
Other languages
English (en)
Inventor
Fritz Wrwag
Marcus Wrwag
Original Assignee
Woerwag Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woerwag Pharma Gmbh & Co Kg filed Critical Woerwag Pharma Gmbh & Co Kg
Publication of AR123714A1 publication Critical patent/AR123714A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un agente para el tratamiento y la profilaxis de la demencia (enfermedades) y la disfunción mitocondrial, en particular, a un suplemento medicinal o nutricional y su uso, que contiene una combinación de biofactores que comprende al menos orotato de magnesio y ácido fólico o folatos. Reivindicación 1: Agentes que comprenden orotato de magnesio y ácido fólico o folatos o tautómeros y sales de los mismos para su uso en la profilaxis y el tratamiento de la demencia. Reivindicación 8: Preparaciones farmacéuticas que contengan un agente para usar de acuerdo con cualquiera de las reivindicaciones 1 a 7, dado el caso junto con excipientes adecuados, en particular, en forma de gotas, jugo, jarabe, comprimidos, grageas, cápsulas, formulaciones de liberación prolongada, infusiones, ungüentos, emulsiones, talcos, polvos.
ARP210102785A 2020-10-07 2021-10-07 Biofactores para el tratamiento y la profilaxis de la demencia AR123714A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20200644.1A EP3981407A1 (de) 2020-10-07 2020-10-07 Biofaktoren zur behandlung und prophylaxe von demenz

Publications (1)

Publication Number Publication Date
AR123714A1 true AR123714A1 (es) 2023-01-04

Family

ID=72801432

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102785A AR123714A1 (es) 2020-10-07 2021-10-07 Biofactores para el tratamiento y la profilaxis de la demencia

Country Status (14)

Country Link
EP (2) EP3981407A1 (es)
JP (1) JP2023545721A (es)
KR (1) KR20230121996A (es)
CN (1) CN116322695A (es)
AR (1) AR123714A1 (es)
BR (1) BR112023006333A2 (es)
CA (1) CA3198067A1 (es)
CL (1) CL2023001016A1 (es)
CO (1) CO2023004351A2 (es)
MX (1) MX2023004107A (es)
PE (1) PE20231320A1 (es)
TW (1) TW202237121A (es)
WO (1) WO2022074114A1 (es)
ZA (1) ZA202304043B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420342B1 (en) * 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
DE102009025549A1 (de) * 2009-06-15 2010-12-16 Werth Akupunktur Center Zusammensetzung für den Transport von Orotsäure über die Bluthirnschranke
US20150132273A1 (en) 2013-11-09 2015-05-14 Rhett Sean Daniels Nutritional Compositions and Methods for Treating Cognitive Impairment
WO2017059895A1 (en) 2015-10-07 2017-04-13 Parthenogen Sagl Dietary supplementation to achieve oxy-redox homeostasis and genomic stability
EP3443965A4 (en) 2016-04-15 2020-02-19 Hirokawa, Yoshihiro MEANS FOR HEALING THE COGNITIVE FUNCTION
DE202017006840U1 (de) * 2017-03-03 2018-07-26 Glycana UG (haftungsbeschränkt) Nahrungsergänzungsmittel umfassend einen Galaktose-haltigen Multivitamin-Mineralstoffkomplex

Also Published As

Publication number Publication date
WO2022074114A1 (de) 2022-04-14
EP3981407A1 (de) 2022-04-13
EP4225318A1 (de) 2023-08-16
CO2023004351A2 (es) 2023-07-10
JP2023545721A (ja) 2023-10-31
CN116322695A (zh) 2023-06-23
PE20231320A1 (es) 2023-08-24
CA3198067A1 (en) 2022-04-14
MX2023004107A (es) 2023-08-07
BR112023006333A2 (pt) 2023-05-09
TW202237121A (zh) 2022-10-01
CL2023001016A1 (es) 2023-11-17
ZA202304043B (en) 2024-04-24
KR20230121996A (ko) 2023-08-22

Similar Documents

Publication Publication Date Title
PE20190738A1 (es) Formulacion novedosa para administracion por via oral
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
PE20190390A1 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
CO6280475A2 (es) Metodo para tratar la deficiencia de vitamina b12
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
CL2021001536A1 (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
CL2021000793A1 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
WO2020044119A3 (en) Oral formulations of lavender and cannabinoids
GT200600263A (es) Regimen de dosificacion para prasugrel
WO2003068231A3 (de) Mittel, enthaltend folsäure, vitamin b6 und vitamin b12, und dessen verwendung
AR123714A1 (es) Biofactores para el tratamiento y la profilaxis de la demencia
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
US8197871B2 (en) Composition for headache treatment
ES2526359T3 (es) Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos
CL2023000764A1 (es) Formas farmacéuticas multipartículas que comprenden deutetrabenazina
ES2180446B1 (es) Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
BR0112830A (pt) Medicamento destinado especialmente a combater as disfunções sexuais
CL2022000095A1 (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
CL2020002369A1 (es) Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina
WO2019004984A3 (en) PHARMACEUTICAL FORMULATION COMPRISING CHOLECALCIFEROL
AR108792A1 (es) Composiciones que comprenden timolol
RU2016147455A (ru) Способ лечения кожных проявлений склеродермии
AR009338A1 (es) Composicion de dosis de unidad multivitaminica y usos de dicha composicion de dosis
TR201714150A1 (tr) Kolekalsiferol İçeren Efervesan Tablet Formunda Bir Farmasötik Formülasyon.
CL2017003178A1 (es) Composición nutricional complementaria formada por ginseng rojo coreano, cafeina, bacillus coagulans, vitamina b6, vitamina b12, selenio, magnesio y excipientes farmacéutica y nuricionalmente aceptables, para mejorar el rendimiento físico y mental.